Tactile Systems Technology, Inc. — Cyborg Score 7/10

Solid
Medical Devices - Therapeutic Compression & Airway Clearance

Strategic Profile

The company offers multiple proprietary devices including Flexitouch Plus for lymphedema treatment, Entre Plus System for compression therapy, Nimbl for upper extremity treatment, and AffloVest for airway clearance. Recently, Tactile acquired LymphaTech Inc. in February 2026 for $6.8 million upfront, adding a 3D measurement platform designed specifically for lymphedema management, strengthening its market position through strategic portfolio expansion.

Cyborg Score Rationale

The company projects 2026 revenue growth of 8-11%, though this accounts for headwinds from new Medicare prior authorization requirements for pneumatic compression devices. A robust cash position of $83.4 million supports continued investment and acquisition strategy, though regulatory headwinds present near-term execution risk.

Top Insights

  • February 2026 acquisition of LymphaTech adds digital 3D measurement technology to expand lymphedema detection and monitoring capabilities
  • 2026 guidance targets $357M-$365M revenue and $49M-$51M adjusted EBITDA, maintaining mid-single-digit growth momentum
  • Medicare prior authorization requirement for pneumatic compression represents a near-term regulatory headwind requiring managed reimbursement navigation
  • Stock trades at 21.47 trailing P/E, below S&P 500's 25 average, suggesting potential undervaluation relative to growth trajectory

Named Competitors

  • Compression Therapy Devices — Traditional and emerging competitors in pneumatic compression space
  • Digital Health Platforms — 3D measurement and monitoring platform for lymphedema

Recent Developments

  • (February 2026) Acquired LymphaTech for $6.8M upfront to expand lymphedema portfolio with digital 3D measurement technology
  • (February 2026) Reported 2025 FY revenue of $329.5M (+12% YoY) with robust $83.4M cash position
  • (February 2026) Issued 2026 guidance of $357M-$365M revenue (+8-11%) and $49M-$51M adjusted EBITDA despite Medicare prior authorization headwinds

Open the full interactive Tactile Systems Technology, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →